Mylan to Acquire Generics Business of Merck KGaA

doi:10.3833/pdr.v2007i84.339

Pharma Deals Review, Vol 2007, No 84 (2007)

Mylan to Acquire Generics Business of Merck KGaA

Business Review Editor

Abstract

Mylan Laboratories entered into agreement to acquire Merck KGaA’s generic business, strengthening its product portfolio with generics. The deal would worth up to €4.9 B (US$6.6 B) to Merck KGaA.

Full Text: pdf

Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.